Improving prognostication in rare metastatic cancers treated with novel immunotherapy: Comparing transversal versus longitudinal assessment and molecular versus radiological response criteria.

Crombé A

Open source

DOI
10.1016/j.diii.2026.03.004
Published
2026 Sep
Container
Diagnostic and interventional imaging
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.diii.2026.03.004,
  title = {Improving prognostication in rare metastatic cancers treated with novel immunotherapy: Comparing transversal versus longitudinal assessment and molecular versus radiological response criteria.},
  author = {Crombé A},
  year = {2026},
  journal = {Diagnostic and interventional imaging},
  doi = {10.1016/j.diii.2026.03.004},
  url = {https://doi.org/10.1016/j.diii.2026.03.004}
}

RIS

TY  - JOUR
TI  - Improving prognostication in rare metastatic cancers treated with novel immunotherapy: Comparing transversal versus longitudinal assessment and molecular versus radiological response criteria.
AU  - Crombé A
PY  - 2026
JO  - Diagnostic and interventional imaging
DO  - 10.1016/j.diii.2026.03.004
UR  - https://doi.org/10.1016/j.diii.2026.03.004
ER  - 

APA

A, C. (2026). Improving prognostication in rare metastatic cancers treated with novel immunotherapy: Comparing transversal versus longitudinal assessment and molecular versus radiological response criteria.. Diagnostic and interventional imaging. https://doi.org/10.1016/j.diii.2026.03.004

Source records